background image

Paid Clinical Trials Nashville

Discover 1,186 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
Active & ResponsiveNew

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

for
Anatomic Stage II Breast Cancer AJCC v8,
Location: Nashville TN
Sponsor: Vandana Abramson

Sex: All

Age: 18+

Code: NCT07016399

Phase2, Recruiting
Active & ResponsiveNew

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

for
Non-muscle Invasive Bladder Cancer
Location: Nashville TN, Myrtle Beach SC
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07206225

Phase1, Recruiting
Active & Responsive

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

for
Cervical Cancer,
Location: Nashville TN, Iowa City IA, Hamilton, Houston TX,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT04895709

Phase1, Phase2, Recruiting
Active & Responsive

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

for
Metastatic Castration-resistant Prostate Cancer
Location: Nashville TN, Birmingham AL, Athens GA, Chicago IL,
Sponsor: Celgene

Sex: Male

Age: 18+

Code: NCT06764485

Phase3, Recruiting
Active & Responsive

Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)

for
Tachycardia, Ventricular
Location: Nashville TN, Saint Louis MO, Columbus OH,
Sponsor: Varian, a Siemens Healthineers Company

Sex: All

Age: 18+

Code: NCT05765175

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

for
Small Cell Lung Cancer
Location: Nashville TN, Chicago IL, Milwaukee WI, Buffalo NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06780137

Phase1, Phase2, Recruiting
Active & Responsive

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Nashville TN, Indianapolis IN, St Louis MO, Chicago IL,
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05216432

Phase1, Recruiting
Active & Responsive

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

for
Primary Myelofibrosis,
Location: Nashville TN, Toronto
Sponsor: GlaxoSmithKline

Sex: All

Age: 18+

Code: NCT06517875

Phase2, Recruiting
Active & Responsive

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

for
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Location: Nashville TN, Huntersville NC, Fairfax VA,
Sponsor: Phanes Therapeutics

Sex: All

Age: 18+

Code: NCT05431270

Phase1, Phase2, Recruiting
Active & Responsive

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

for
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor,
Location: Nashville TN, Chicago IL, Warrenville IL, Ann Arbor MI,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 12+

Code: NCT04924075

Phase2, Recruiting